Sarmazenil
![]() | |
| Gene therapy | |
|---|---|
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| ATCvet code | |
| Physiological data | |
| Legal status | |
| Pharmacokinetic data | |
| Identifiers | |
| |
| CAS Number | |
| PubChem Template:Abbreviation | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C15H14ClN3O3 |
| Molar mass | 319.743 g/mol |
| 3D model (JSmol) | |
| |
| |
| Template:Xmark | |
|
WikiDoc Resources for Sarmazenil |
|
Articles |
|---|
|
Most recent articles on Sarmazenil |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Sarmazenil at Clinical Trials.gov Clinical Trials on Sarmazenil at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Sarmazenil
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Sarmazenil Discussion groups on Sarmazenil Patient Handouts on Sarmazenil Directions to Hospitals Treating Sarmazenil Risk calculators and risk factors for Sarmazenil
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Sarmazenil |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Sarmazenil (Ro15-3505) is a drug from the benzodiazepine family. It acts as a partial inverse agonist of benzodiazepine receptors,[1] meaning that it causes the opposite effects to most benzodiazepine drugs, and instead acts as an anxiogenic and convulsant. It is used in veterinary medicine to reverse the effects of benzodiazepine sedative drugs in order to rapidly re-awaken anesthetized animals.[2][3][4]
See also
References
- ↑ López-Romero B, Evrard G, Durant F, Sevrin M, George P (1998). "Molecular structure and stereoelectronic properties of sarmazenil--a weak inverse agonist at the omega modulatory sites (benzodiazepine receptors): comparison with bretazenil and flumazenil". Bioorganic and Medicinal Chemistry. 6 (10): 1745–57. doi:10.1016/S0968-0896(98)00117-5. PMID 9839004.
- ↑ Henke J, Roberts U, Otto K, Lendl C, Matis U, Brill T, Erhardt W (1996). "Clinical investigations of an i.m. combination anesthesia with fentanyl / climazolam / xylazine and postoperative i.v. antagonism with naloxone / sarmazenil / yohimbine in guinea pigs". Tierärztliche Praxis (in German). 24 (1): 85–7. PMID 8720962.
- ↑ Janovsky M, Tataruch F, Ambuehl M, Giacometti M (2000). "A Zoletil-Rompun mixture as an alternative to the use of opioids for immobilization of feral red deer". Journal of Wildlife Diseases. 36 (4): 663–9. doi:10.7589/0090-3558-36.4.663. PMID 11085427.
- ↑ Walzer C, Huber C (2002). "Partial antagonism of tiletamine-zolazepam anesthesia in cheetah". Journal of Wildlife Diseases. 38 (2): 468–72. doi:10.7589/0090-3558-38.2.468. PMID 12038151.
- CS1 maint: Multiple names: authors list
- CS1 maint: Unrecognized language
- Articles with short description
- Template:drugs.com link with non-standard subpage
- Articles with changed ChemSpider identifier
- Articles with changed EBI identifier
- Infobox-drug molecular-weight unexpected-character
- Articles with changed InChI identifier
- Pages using infobox drug with unknown parameters
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- GABAA receptor negative allosteric modulators
- Convulsants
- Anxiogenics
- Lactams
- Organochlorides
- Imidazobenzodiazepines
- Carboxylate esters
- Ethyl esters
- Drug
